Wolin, E., Mita, A., Mahipal, A., Meyer, T., Bendell, J., Nemunaitis, J., . . . Mita, M. (2019). A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.
Citación estilo ChicagoWolin, Edward, et al. A Phase 2 Study of an Oral MTORC1/mTORC2 Kinase Inhibitor (CC-223) for Non-pancreatic Neuroendocrine Tumors With or Without Carcinoid Symptoms. 2019.
Cita MLAWolin, Edward, et al. A Phase 2 Study of an Oral MTORC1/mTORC2 Kinase Inhibitor (CC-223) for Non-pancreatic Neuroendocrine Tumors With or Without Carcinoid Symptoms. 2019.
Precaución: Estas citas no son 100% exactas.